Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

Cyclooxygenase-1

Also: PTGS1 · id COX-1

Constitutive isoform that produces prostaglandins maintaining gastric mucosa, platelet function, and renal blood flow. Non-selective NSAID inhibition drives GI and bleeding risk.

16 drugs act here9 plants reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on Cyclooxygenase-1

These medications have Cyclooxygenase-1 among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

Botanical connections

Plants whose compounds act on Cyclooxygenase-1

Each plant below contains a named compound documented to act on Cyclooxygenase-1. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.

  • Phenethyl ferulatePhenolic acid ester

    Identified in vitro as a principal active constituent responsible for cyclooxygenase and 5-lipoxygenase inhibitory activity in n-hexane extracts; content correlated with inhibitory potency across commercial samples (Zschocke et al., 1997).

  • FalcarindiolPolyacetylene (polyyne)

    Reported in vitro to inhibit 5-lipoxygenase and cyclooxygenase (Zschocke et al., 1997); additionally reported to activate Nrf2/ARE pathway, inducing antioxidant and phase-2 drug-metabolizing enzymes in cultured hepatic cells (Ohnuma et al., 2009); also demonstrated partial PPARγ agonism in reporter assays (Atanasov et al., 2013).

  • (-)-Bornyl ferulatePhenolic acid ester

    Identified as a minor active constituent contributing to cyclooxygenase and 5-lipoxygenase inhibition in vitro (Zschocke et al., 1997).

  • Procyanidins / Flavanols (epicatechin, catechin)Polyphenols

    Studies report inhibition of platelet activation, modulation of eicosanoid pathways, and upregulation of nitric oxide bioavailability. Murphy et al. (2003) reported inhibition of platelet function in healthy volunteers following cocoa flavanol supplementation.

  • Apigenin / LuteolinFlavonoids

    Preclinical studies suggest inhibition of cyclooxygenase isoforms and NF-κB-mediated inflammatory signalling; clinical translation not yet established from provided citations.

  • EugenolPhenylpropanoid

    Preclinical studies report eugenol inhibits COX-1/COX-2 and NF-κB signalling, suppresses PGE2 synthesis, and modulates TRPV1 and voltage-gated sodium channels; proposed as the primary driver of observed analgesic and anti-inflammatory signals.

  • RutaecarpineIndoloquinazolinone alkaloid

    Chiou et al. (1996) reported nitric oxide-dependent vasodilatation (full, 100% endothelium-dependent) in isolated rat aorta. Sheu et al. (2000) reported antithrombotic activity in a murine model, with prolongation of platelet plug occlusion time compared with aspirin on a molar basis.

  • Methyl salicylateSalicylate ester

    Methyl salicylate shares cyclooxygenase-inhibiting mechanism with salicylate class compounds; relevance at concentrations achieved from plant use is unclear.

  • SalicinPhenolic glycoside

    Hepatically metabolized to salicylic acid — chemically the active metabolite of aspirin. The mechanism overlap with NSAIDs is therefore direct rather than analogous.

  • Salicylate fractionsalicylate (aspirin precursor)

    The genus name Spiraea (older botanical name) gave aspirin its name — Bayer's 1899 acetylsalicylic acid was developed from spiraein extracted from this plant. Salicylate-induced COX inhibition produces analgesic, anti-inflammatory, and antipyretic effects, weaker but mechanistically identical to aspirin.

  • Salicylic acidPhenolic acid

    Salicylic acid is a recognized COX pathway modulator; direct attribution of this activity to Iris versicolor preparations has not been established in verified clinical literature.

A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.